Portal de Periódicos da CAPES

Pediatric Cardiomyopathy: Importance of Genetic and Metabolic Evaluation

2012; Elsevier BV; Volume: 18; Issue: 5 Linguagem: Inglês

10.1016/j.cardfail.2012.01.017

1532-8414

Steven J. Kindel, Erin M. Miller, Resmi Gupta, Linda Cripe, Robert B. Hinton, Robert L. Spicer, Jeffrey A. Towbin, Stephanie M. Ware,

Cardiovascular Function and Risk Factors

Background Cardiomyopathy is a heterogeneous disease with a strong genetic component. A research-based pediatric cardiomyopathy registry identified familial, syndromic, or metabolic causes in 30% of children. However, these results predated clinical genetic testing. Methods and Results We determined the prevalence of familial, syndromic, or metabolic causes in 83 consecutive unrelated patients referred for genetic evaluation of cardiomyopathy from 2006 to 2009. Seventy-six percent of probands (n = 63) were categorized as familial, syndromic, or metabolic. Forty-three percent (n = 18) of hypertrophic cardiomyopathy (HCM) patients had mutations in sarcomeric genes, with MYH7 and MYBPC3 mutations predominating. Syndromic (17%; n = 7) and metabolic (26%; n = 11) causes were frequently identified in HCM patients. The metabolic subgroup was differentiated by decreased endocardial shortening fraction on echocardiography. Dilated cardiomyopathy (DCM) patients had similar rates of syndromic (20%; n = 5) and metabolic (16%; n = 4) causes, but fewer familial cases (24%; n = 6) compared with HCM patients. Conclusions The cause of cardiomyopathy is identifiable in a majority of affected children. An underlying metabolic or syndromic cause is identified in >35% of children with HCM or DCM. Identification of etiology is important for management, family-based risk assessment, and screening.